At Lunoxy Medical, this is exactly why we built a personalized primary care model: time, fundamentals, and real solutions
The US Food and Drug Administration approved this first-in-class medication for the management of type 2 diabetes (T2D) in 2022 [2], for the reduction of excess weight in adults with obesity or overweight in 2023 [3], and for moderate-to-severe obstructive sleep apnea (OSA) in people with obesity in 2024 [4]
The three validated injection sites are: the lower abdomen (at least 5 cm from the navel), the outer thigh, and the outer upper arm
Protandim Protects Oligodendrocytes against an Oxidative Insult
It is designated as a research chemical and is for in-vitro testing and laboratory experimentation
Medium-chain triglycerides: an update